Daewoong Pharma (069620) Stock Price & News

069620:KRX

Daewoong Pharma

₩105 000,00

0,00%

(0,00) 1D

16 Okt., 15:30:30 GMT+9 · KRW

All symbols

	Symbol	Price	Change	% Change

Generating top insights for 069620...

Open

₩105 600

High

₩109 600

Low

₩105 000

Mkt. cap

1,22 bn

Avg. vol.

18,62 k

Volume

21,59 k

Dividend

0,57%

Quarterly dividend

₩150

Ex-dividend date

27 Des. 2023

P/E ratio

6,18

52-wk high

₩199 400

52-wk low

₩101 900

EPS

₩16 988

Shares outstanding

11,59 m

No. of employees

2 k

Open

₩105 600

High

₩109 600

Low

₩105 000

Mkt. cap

1,22 bn

Avg. vol.

18,62 k

Volume

21,59 k

Dividend

0,57%

Quarterly dividend

₩150

Ex-dividend date

27 Des. 2023

P/E ratio

6,18

52-wk high

₩199 400

52-wk low

₩101 900

EPS

₩16 988

Shares outstanding

11,59 m

No. of employees

2 k

Related stocks

News stories

From web sources and news partners

Yahoo Finance

1 uur gelede

SK hynix (NasdaqGS:SKHY) Seeks US Clearance For China Chip Gear Plan

The Motley Fool

8 minute gelede

The 10-Year Treasury Is Above 5% for the First Time in Almost 20 Years. History Says This Is How the S&P 500 Index Will Perform Over the Next 12 Months.

Crypto Briefing

4 minute gelede

Morgan Stanley ties S&P 500 growth to a $1.6 trillion AI spending wave

AOL.com

2 uur gelede

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

Profile

Daewoong Pharmaceutical Co., Ltd. is a pharmaceutical company headquartered in Seoul, South Korea. Daewoong Pharmaceutical primarily engages in the manufacture of pharmaceutical products, including prescription and over-the-counter healthcare products. Wikipedia

About Daewoong Pharma

CEOChang-jae Lee | Seongsoo Park

Employees1,89 k

Founded1945

Headquarters-

SectorPharmaceutical industry

Websitedaewoong.com

All values in KRW	Sep. 2025	Des. 2025	Mrt. 2026	Jun. 2026
Revenue	411,83 mjd	397,12 mjd	377,80 mjd	448,46 mjd
Cost of goods sold	198,11 mjd	185,96 mjd	196,61 mjd	199,39 mjd
Cost of revenue	198,11 mjd	185,96 mjd	196,61 mjd	199,39 mjd
Research and development expenses	8,31 mjd	139,98 mjd	16,11 mjd	14,81 mjd
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	144,21 mjd	23,12 mjd	136,65 mjd	154,92 mjd
Operating expense	156,83 mjd	169,10 mjd	158,98 mjd	181,01 mjd
Total operating expenses	354,94 mjd	355,06 mjd	355,59 mjd	380,40 mjd
Operating income	56,89 mjd	42,06 mjd	22,21 mjd	68,07 mjd
Other non operating income	-1,16 mjd	2,77 mjd	1,52 mjd	-36,53 mjd
EBT including unusual items	54,73 mjd	68,97 mjd	33,97 mjd	21,89 mjd
EBT excluding unusual items	54,73 mjd	88,02 mjd	11,82 mjd	21,89 mjd
Income tax expense	7,42 mjd	-16,73 mjd	8,46 mjd	1,98 mjd
Effective tax rate	13,56%	-24,26%	24,89%	9,02%
Other operating expenses	1,17 mjd	1,17 mjd	1,88 mjd	1,61 mjd
Net income	46,37 mjd	89,84 mjd	25,90 mjd	33,37 mjd
Net profit margin	11,26%	22,62%	6,86%	7,44%
Earnings per share	-	-	-	-
Interest and investment income	-	1,12 mjd	1,74 mjd	-
Interest expense	-	-3,53 mjd	-8,00 mjd	-
Net interest expenses	-	-2,41 mjd	-6,26 mjd	-
Depreciation and amortization charges	1,77 mjd	1,43 mjd	1,15 mjd	7,94 mjd
EBITDA	69,45 mjd	56,04 mjd	38,38 mjd	92,95 mjd
Gain or loss from assets sale	-12,80 m	-52,31 mjd	35,01 m	-7,54 m

Ask anything